Milica Kontic

Belgrade, SE, Serbia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab-Chemotherapy: A Real-World Study from Serbia.

Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab-Chemotherapy: A Real-World Study from Serbia.

Journal: Current oncology (Toronto, Ont.)

Published: February 10, 2026

Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression.

Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression.

Journal: Cancers

Published: January 13, 2026

Revealing the Drivers Underlying Distinct Evolutionary Trajectories in Lung Adenocarcinoma.

Revealing the Drivers Underlying Distinct Evolutionary Trajectories in Lung Adenocarcinoma.

Journal: bioRxiv : the preprint server for biology

Published: January 09, 2026

Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis-A Single-Center Experience.

Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis-A Single-Center Experience.

Journal: Medicina (Kaunas, Lithuania)

Published: December 12, 2025

Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.

Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.

Journal: Current oncology (Toronto, Ont.)

Published: December 10, 2025

Immune checkpoints in lung cancer.

Immune checkpoints in lung cancer.

Journal: Breathe (Sheffield, England)

Published: November 10, 2025

Panorama of Chromosomal Instability in Lung Cancer.

Panorama of Chromosomal Instability in Lung Cancer.

Journal: medRxiv : the preprint server for health sciences

Published: September 29, 2025

Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy.

Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy.

Journal: Genes

Published: July 15, 2025

Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.

Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.

Journal: Nature communications

Published: May 29, 2025

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.

Journal: Current oncology (Toronto, Ont.)

Published: May 20, 2025

The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study.

The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study.

Journal: Cancers

Published: April 27, 2025

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia.

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia.

Journal: Biomedicines

Published: April 11, 2025

Showing 1-12 of 49

Last Updated: 09/26/2026